[ad_1]
When not busy attempting to resurrect the wooly mammoth, geneticist George Church spends his time launching new biotech corporations at a tempo practically on par with SpaceX sending rockets into house. Finally rely, he had co-founded or in any other case helped kickstart about 50 completely different corporations – lots of which have gained some quantity of traction. As an example, Ginkgo Bioworks (DNA) acquired considered one of his very first ventures, an artificial biology startup known as Gen9 that we lined on the time. The truth is, we’ve written about various the Harvard professor’s many companies, and even held shares in one other early enterprise, Editas Medication (EDIT), earlier than exiting our place in 2022.
One other considered one of Church’s earliest startups was an organization known as ReadCoor whose mental property (IP) would finally change into a key know-how that’s presently serving to gasoline development for 10X Genomics (TXG). The biotech firm lately launched its 2023 year-end outcomes. Income climbed 20% year-over-year to greater than $618 million after development hit a wall the prior yr in 2022. New product platforms are serving to revive development, although the corporate’s flagship platform remains to be flagging and gross margins are nonetheless shrinking. Let
[ad_2]
Source link
